FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210617201> ?p ?o ?g. }

• W4210617201 endingPage "176" @default.
• W4210617201 startingPage "169" @default.
• W4210617201 abstract "Abstract Crohn’s disease (CD) is associated with reduced quality of life, increased absenteeism and high direct medical costs resulting from frequent hospitalizations and surgeries. Tumor necrosis factor–alpha inhibitors (TNFi’s) have transformed the therapeutic landscape and enabled a shift from a symptom control to a treat-to-target strategy. The Effect of Tight Control Management on Crohn’s Disease (CALM) trial demonstrated tight control (TC), with TNFi dose changes informed by biochemical markers of inflammation, achieved higher mucosal healing rates compared with conventional management (CM) based on symptoms. A Markov model compared TC and CM strategies from the perspective of the Canadian public payer using patient-observation data from the CALM trial. A regression model estimated weekly CD Activity Index–based transition matrices over a 5-year horizon and included covariates to improve extrapolation of outcomes beyond the 48-week trial assessment period. Costs of CD-related hospitalizations, biomarker tests and adalimumab injections were sourced from public data. Other direct medical costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. Absenteeism was monetized and included in a sensitivity analysis. Over the 5-year time horizon, TC reduced hospitalization costs by 64% compared with CM. Other direct medical costs were reduced by 22%; adalimumab costs increased by 38%, generating an ICER of $35,168 per QALY gained. Absenteeism costs were reduced by 54%, and, when that was included in the model, TC became dominant compared with CM. Management of CD with TC is cost-effective compared with CM in Canada and is dominant if indirect costs associated with absenteeism are included. Trial registration number: NCT01235689." @default.
• W4210617201 created "2022-02-08" @default.
• W4210617201 creator A5003715293 @default.
• W4210617201 creator A5008149243 @default.
• W4210617201 creator A5027876343 @default.
• W4210617201 creator A5028386079 @default.
• W4210617201 creator A5036036179 @default.
• W4210617201 creator A5055638169 @default.
• W4210617201 creator A5062818239 @default.
• W4210617201 creator A5072233837 @default.
• W4210617201 creator A5078207979 @default.
• W4210617201 date "2022-03-10" @default.
• W4210617201 modified "2023-10-14" @default.
• W4210617201 title "Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective" @default.
• W4210617201 cites W1991810959 @default.
• W4210617201 cites W2012440800 @default.
• W4210617201 cites W2014298657 @default.
• W4210617201 cites W2025792594 @default.
• W4210617201 cites W2026116536 @default.
• W4210617201 cites W2030491651 @default.
• W4210617201 cites W2056917411 @default.
• W4210617201 cites W2082916124 @default.
• W4210617201 cites W2086096279 @default.
• W4210617201 cites W2088826436 @default.
• W4210617201 cites W2092052931 @default.
• W4210617201 cites W2105246122 @default.
• W4210617201 cites W2107743584 @default.
• W4210617201 cites W2110682994 @default.
• W4210617201 cites W2114843325 @default.
• W4210617201 cites W2118422544 @default.
• W4210617201 cites W2134299051 @default.
• W4210617201 cites W2149170290 @default.
• W4210617201 cites W2151351996 @default.
• W4210617201 cites W2171341132 @default.
• W4210617201 cites W2404725277 @default.
• W4210617201 cites W2581662660 @default.
• W4210617201 cites W2757094555 @default.
• W4210617201 cites W2766046358 @default.
• W4210617201 cites W2766230215 @default.
• W4210617201 cites W2898624288 @default.
• W4210617201 cites W2899003764 @default.
• W4210617201 cites W2899339283 @default.
• W4210617201 cites W2899378522 @default.
• W4210617201 cites W2908547111 @default.
• W4210617201 cites W2921593132 @default.
• W4210617201 cites W2939252709 @default.
• W4210617201 cites W2949937340 @default.
• W4210617201 cites W2960398624 @default.
• W4210617201 cites W2998121352 @default.
• W4210617201 cites W3000656673 @default.
• W4210617201 cites W3012775556 @default.
• W4210617201 cites W3013062810 @default.
• W4210617201 cites W4211241857 @default.
• W4210617201 doi "https://doi.org/10.1093/jcag/gwac001" @default.
• W4210617201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35919766" @default.
• W4210617201 hasPublicationYear "2022" @default.
• W4210617201 type Work @default.
• W4210617201 citedByCount "2" @default.
• W4210617201 countsByYear W42106172012022 @default.
• W4210617201 countsByYear W42106172012023 @default.
• W4210617201 crossrefType "journal-article" @default.
• W4210617201 hasAuthorship W4210617201A5003715293 @default.
• W4210617201 hasAuthorship W4210617201A5008149243 @default.
• W4210617201 hasAuthorship W4210617201A5027876343 @default.
• W4210617201 hasAuthorship W4210617201A5028386079 @default.
• W4210617201 hasAuthorship W4210617201A5036036179 @default.
• W4210617201 hasAuthorship W4210617201A5055638169 @default.
• W4210617201 hasAuthorship W4210617201A5062818239 @default.
• W4210617201 hasAuthorship W4210617201A5072233837 @default.
• W4210617201 hasAuthorship W4210617201A5078207979 @default.
• W4210617201 hasBestOaLocation W42106172011 @default.
• W4210617201 hasConcept C121955636 @default.
• W4210617201 hasConcept C126322002 @default.
• W4210617201 hasConcept C144133560 @default.
• W4210617201 hasConcept C15744967 @default.
• W4210617201 hasConcept C159110408 @default.
• W4210617201 hasConcept C168563851 @default.
• W4210617201 hasConcept C1862650 @default.
• W4210617201 hasConcept C27400517 @default.
• W4210617201 hasConcept C2778260677 @default.
• W4210617201 hasConcept C2779134260 @default.
• W4210617201 hasConcept C2779280984 @default.
• W4210617201 hasConcept C2779951463 @default.
• W4210617201 hasConcept C2780132546 @default.
• W4210617201 hasConcept C6964187 @default.
• W4210617201 hasConcept C71924100 @default.
• W4210617201 hasConcept C77805123 @default.
• W4210617201 hasConceptScore W4210617201C121955636 @default.
• W4210617201 hasConceptScore W4210617201C126322002 @default.
• W4210617201 hasConceptScore W4210617201C144133560 @default.
• W4210617201 hasConceptScore W4210617201C15744967 @default.
• W4210617201 hasConceptScore W4210617201C159110408 @default.
• W4210617201 hasConceptScore W4210617201C168563851 @default.
• W4210617201 hasConceptScore W4210617201C1862650 @default.
• W4210617201 hasConceptScore W4210617201C27400517 @default.
• W4210617201 hasConceptScore W4210617201C2778260677 @default.
• W4210617201 hasConceptScore W4210617201C2779134260 @default.
• W4210617201 hasConceptScore W4210617201C2779280984 @default.

• next